AI Article Synopsis
- Doctors have found new drugs that help treat a type of kidney cancer called metastatic renal cell carcinoma (mRCC), which targets specific proteins in the body.
- With these new treatments, patients can now live about 2 years longer than before they started using these medications.
- Scientists are now trying to figure out what signs they can look for to predict how well patients will respond to these new drugs and improve treatment options even further.
Article Abstract
The medical treatment of metastatic renal cell carcinoma (mRCC) has undergone a paradigm shift during the last decade with the approval of five drugs targeting vascular endothelial growth factor (VEGF) or its receptors (bevacizumab, sunitinib, sorafenib, pazopanib and axitinib) and of two drugs inhibiting the PI3K/AKT/mTOR (mammalian target of rapamycin) pathway (temsirolimus and everolimus). Median survival has now reached 2 years in mRCC patients receiving first-line targeted treatment. A considerable body of work was conducted on the identification of prognostic factors of survival in the earlier era of immunotherapy of mRCC. The current challenge is to pursue this work on biomarkers of prognosis for targeted therapy and, even more importantly, to identify predictive factors of response to such therapy. This review provides an overview of recent key work on prognostic and predictive factors in patients with advanced clear cell RCC treated with VEGF-targeted agents.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1586/14737140.2014.882773 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
CD36 as a Therapeutic Target in Tumor Microenvironment and Lipid Metabolism.
Anticancer Agents Med Chem
January 2025
Cancer Center, The Second Hospital of Shandong University, Jinan, Shandong, 250033, China.
Dysregulated lipid metabolism within the tumor microenvironment (TME) is a critical hallmark of cancer progression, with lipids serving as a major energy source for tumor cells. Beyond their role in cell membrane synthesis, lipids also provide essential substrates for biomolecule production and activate signaling pathways that regulate various cellular processes. Aberrant lipid metabolism impacts not only function but also alters the behavior of immune and stromal cells within the TME.
View Article and Find Full Text PDFAn Updated Review on Dysregulated lncRNAs and their Contribution to the Various Molecular Types of Lung Carcinoma.
Anticancer Agents Med Chem
January 2025
Stem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Lung cancer is correlated with a high death rate, with approximately 1.8 million mortality cases reported worldwide in 2022. Despite development in the control of lung cancer, most cases are detected at higher stages with short survival rates.
View Article and Find Full Text PDFEffect of zoledronic acid on biological characteristics of cervical cancer cells.
Afr J Reprod Health
November 2024
Department of Obstetrics and Gynecology, Wuxi No.2 People's Hospital, Wuxi 214002, Jiangsu Province, China.
Cervical cancer (CC) is a malignant tumor in females characterized by high incidence and mortality rates, often resulting in a poor prognosis for patients. Zoledronic acid (ZA), a third-generation bisphosphonate, exhibits anti-tumor properties across various types of tumors. To further understand the effect of ZA in the treatment of CC, this article included two kinds of human CC cells (CCCs) as the research object, examining the impact of varying levels of ZA on the cells' biological properties.
View Article and Find Full Text PDFA prospective, phase II, neoadjuvant study based on chemotherapy sensitivity in HR+/HER2- breast cancer-FINEST study.
Cancer Commun (Lond)
January 2025
Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Centre, Shanghai, P. R. China.
Background: Hormone receptor-positive (HR+)/humaal growth factor receptor 2-negative (HER2-) breast cancer, the most common breast cancer type, has variable prognosis and high recurrence risk. Neoadjuvant therapy is recommended for median-high risk HR+/HER2- patients. This phase II, single-arm, prospective study aimed to explore appropriate neoadjuvant treatment strategies for HR+/HER2- breast cancer patients.
View Article and Find Full Text PDFCharacteristics of Soluble PD-L1 and PD-1 Expression and Their Correlations With Immune Status and Prognosis in Advanced Lung Cancer.
Asia Pac J Clin Oncol
January 2025
Department of Respiratory and Critical Care Medicine, Peking University People's Hospital, Beijing, China.
Purpose: Our study aims to evaluate the characteristics of serum soluble PD-1 (sPD-1) and soluble PD-L1 (sPD-L1) levels and their correlations with immune status and prognosis in advanced lung cancer patients.
Methods: Patients diagnosed with advanced lung cancer based on histology or cytology in Peking University People's Hospital from July 2020 to November 2021 were enrolled. Clinicopathological data were recorded and analyzed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!